396 related articles for article (PubMed ID: 2868819)
1. The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.
Lennard MS; Tucker GT; Woods HF
Clin Pharmacokinet; 1986; 11(1):1-17. PubMed ID: 2868819
[TBL] [Abstract][Full Text] [Related]
2. Oxidation phenotype and the metabolism and action of beta-blockers.
Lennard MS
Klin Wochenschr; 1985 Apr; 63(7):285-92. PubMed ID: 2860267
[TBL] [Abstract][Full Text] [Related]
3. Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol.
Lennard MS; Tucker GT; Silas JH; Woods HF
Xenobiotica; 1986 May; 16(5):435-47. PubMed ID: 2874665
[TBL] [Abstract][Full Text] [Related]
4. Polymorphic metabolism of beta-adrenoceptor antagonists.
Silas JH; Lennard MS; Tucker GT; Ramsay LE; Woods HF
Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):11S-19S. PubMed ID: 6146335
[TBL] [Abstract][Full Text] [Related]
5. Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.
McGourty JC; Silas JH; Lennard MS; Tucker GT; Woods HF
Br J Clin Pharmacol; 1985 Dec; 20(6):555-66. PubMed ID: 2868742
[TBL] [Abstract][Full Text] [Related]
6. Stereo- and regioselectivity of hepatic oxidation in man--effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation.
Dayer P; Leemann T; Küpfer A; Kronbach T; Meyer UA
Eur J Clin Pharmacol; 1986; 31(3):313-8. PubMed ID: 2878813
[TBL] [Abstract][Full Text] [Related]
7. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.
Lennard MS; Jackson PR; Freestone S; Tucker GT; Ramsay LE; Woods HF
Br J Clin Pharmacol; 1984 Jun; 17(6):679-85. PubMed ID: 6743465
[TBL] [Abstract][Full Text] [Related]
8. Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.
Lennard MS; Silas JH; Freestone S; Trevethick J
Br J Clin Pharmacol; 1982 Aug; 14(2):301-3. PubMed ID: 6125207
[TBL] [Abstract][Full Text] [Related]
9. Bufuralol metabolism in human liver: a sensitive probe for the debrisoquine-type polymorphism of drug oxidation.
Minder EI; Meier PJ; Müller HK; Minder C; Meyer UA
Eur J Clin Invest; 1984 Jun; 14(3):184-9. PubMed ID: 6147254
[TBL] [Abstract][Full Text] [Related]
10. Polymorphic metabolism of the beta-adrenoreceptor blocking drugs and its clinical relevance.
Smith RL
Eur J Clin Pharmacol; 1985; 28 Suppl():77-84. PubMed ID: 2865154
[TBL] [Abstract][Full Text] [Related]
11. Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics.
Lewis RV; Lennard MS; Jackson PR; Tucker GT; Ramsay LE; Woods HF
Br J Clin Pharmacol; 1985 Mar; 19(3):329-33. PubMed ID: 2859048
[TBL] [Abstract][Full Text] [Related]
12. Debrisoquine-type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation.
Gut J; Gasser R; Dayer P; Kronbach T; Catin T; Meyer UA
FEBS Lett; 1984 Aug; 173(2):287-90. PubMed ID: 6146537
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacokinetic and clinical consequences of the genetic polymorphism of oxidation].
Dayer P; Courvoisier F; Kupfer A; Balant-Gorgia A; Balant L; Fabre J
Schweiz Med Wochenschr; 1983 Feb; 113(8):295-7. PubMed ID: 6133350
[TBL] [Abstract][Full Text] [Related]
14. Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol.
Dayer P; Balant L; Kupfer A; Striberni R; Leemann T
Eur J Clin Pharmacol; 1985; 28(3):317-20. PubMed ID: 2861095
[TBL] [Abstract][Full Text] [Related]
15. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
[TBL] [Abstract][Full Text] [Related]
16. Relationship between oxidative metabolism of 2-acetylaminofluorene, debrisoquine, bufuralol, and aldrin in human liver microsomes.
McManus ME; Boobis AR; Minchin RF; Schwartz DM; Murray S; Davies DS; Thorgeirsson SS
Cancer Res; 1984 Dec; 44(12 Pt 1):5692-7. PubMed ID: 6498831
[TBL] [Abstract][Full Text] [Related]
17. Timolol metabolism and debrisoquine oxidation polymorphism: a population study.
Lennard MS; Lewis RV; Brawn LA; Tucker GT; Ramsay LE; Jackson PR; Woods HF
Br J Clin Pharmacol; 1989 Apr; 27(4):429-34. PubMed ID: 2719899
[TBL] [Abstract][Full Text] [Related]
18. The oral clearance and beta-adrenoceptor antagonist activity of propranolol after single dose are not related to debrisoquine oxidation phenotype.
Lennard MS; Jackson PR; Freestone S; Ramsay LE; Tucker GT; Woods HF
Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):106S-107S. PubMed ID: 6146334
[No Abstract] [Full Text] [Related]
19. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency.
Dayer P; Kronbach T; Eichelbaum M; Meyer UA
Biochem Pharmacol; 1987 Dec; 36(23):4145-52. PubMed ID: 3689440
[TBL] [Abstract][Full Text] [Related]
20. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.
Horai Y; Taga J; Ishizaki T; Ishikawa K
Br J Clin Pharmacol; 1990 Jan; 29(1):111-5. PubMed ID: 2297455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
